Combination of genome editing and human pluripotent stem cells (hPSCs) offers a platform for in vitro disease modeling, drug discovery and personalized stem cell therapeutics. However, incorporation of large modifications using CRISPR/Cas9-based genome editing in hPSCs typically requires the use of selection markers due to low editing efficiencies. Here we report a novel editing technology in hPSCs using Cas9 protein complexed with chemically modified single guide RNA (sgRNA) and recombinant AAV6 (rAAV6) vectors for donor delivery without marker selection. With these components, we demonstrate targeted integration of a 2.2 kb DNA expression cassette in hPSCs at frequencies up to 94% and 67% at the HBB and MYD88 loci, respectively. We used this protocol to correct the homozygous sickle cell disease (SCD) mutation in an iPSC line derived from a SCD patient with a frequency of 63%. This Cas9/AAV6 system allows for both the integration of large gene cassettes and the creation of single nucleotide changes in hPSCs at high frequencies, eliminating the need for multiple editing steps and marker selection, thus increasing the potential of editing human pluripotent cells for both research and translational applications.
oligodeoxynucleotides (ssODNs), has been applied to hPSCs to create small edits (<10bp) at high efficiency 1 
.
This strategy enables the modeling of diseases caused by single or several base pair mutations, which is frequently the case for genetic disorders. The ssODN approach, however, does not allow the targeted integration of large gene cassettes which is needed for certain gene correction type approaches and for many research applications. For example, to make reporter cell lines to study a disease, targeted integration of large gene fragments (>1kb) is required in order to integrate a reporter gene as a marker for differentiation, which can be important for biological understanding and clinical application of hPSCs. Large gene integration is impractical using the current Cas9/ssODN technology due to inverse correlation between ssODN size and editing efficiency (most efficient size is 90bp) 2 . Other systems, such as iCRISPR, can yield high frequencies in embryonic stem cells (ESCs) of around 30% 3 for small base pair edits, however this efficiency is dramatically reduced to <1% 4 when large insertions are introduced. To obtain a large population of edited cells with a protocol that yields such low editing frequencies requires the use of a selection marker, which could affect cell function, thereby limiting research and clinical relevance. To avoid the possible influence of a selection marker, piggyBac or Cre/loxP systems have been used to excise this marker. However, both of these approaches require an additional editing step and the use of piggyBac requires a nearby TTAA site 5 .
It was recently shown that large ssODN donor vectors are able to incorporate large modifications at high editing frequencies when delivered directly into zygotes by microinjection 6 . Though microinjection is impractical for editing large populations of hPSCs, we hypothesized that efficient delivery of donor vectors into the nucleus is a limiting aspect for editing frequency.
Along these lines, we previously reported that the combination of adeno-associated virus (AAV), chemically-modified singe-stranded guide RNA (sgRNA), and Cas9 elicits high editing frequencies in human primary CD34+ hematopoietic stem cells, a cell type that has been refractory to previous genome editing protocols, suggesting that AAV vectors may efficiently deliver large donor constructs to the nucleus [7] [8] [9] To test this hypothesis, we assessed the targeting frequency at the HBB locus of a large expression cassette (2.2kb; GFP driven by a UbC promoter) in human H9 ESCs using AAV6 as a donor delivery vehicle ( Figure 1a) . We electroporated cells with Cas9 ribonucleoprotein (RNP) complexed with a chemically-modified sgRNA 10 targeted to exon 1 of the HBB gene, then immediately (<5 minutes) afterward transduced the electroporated cells with AAV6 donor vector. Our UbC-GFP donor expresses GFP episomally, therefore we assessed editing frequency at an average of 42.27% + 0.07% after non-integrated AAV6 episomal expression was diluted out as the population of cells expanded post-editing, a process that occurred within 4 days (Figure 1b) . Using this approach, we observed a population of highly edited ESCs stably expressing GFP at an average frequency of 53.7% + 0.11% compared to plasmid-based vector (0.34% + 0.002%) at four days post-editing ( Figure   1c,d ). We then sought to determine whether this same approach could achieve high editing frequencies in iPSC lines at similar efficiencies. Indeed, when targeting the HBB locus with our UbC-GFP AAV6 donor vector in five different induced pluripotent stem cell (iPSC) lines we observed editing frequencies at an average of 51.28% + 0.12% (Figure 1e ).
In an effort to further improve these targeting rates we next optimized variables within the protocol. Increasing the amounts of Cas9 during electroporation increased targeting frequencies at both the HBB and MYD88 loci in a dose-dependent manner (Figure 1f ). Finally, we tested different electroporation programs and found that CA137 protocol of the Lonza 4-D system was able to more than double the editing frequency at the HBB locus compared to the previously used CB150 (84% vs. 41%, respectively, Figure 1g ).
Combining the fully optimized conditions (150µg/mL Cas9 with CA137 electroporation program), we observed 91% targeted integration at HBB and 59% at MYD88 in ESCs ( Figure   2a ). To analyze whether cells possessed mono-or bi-allelic integrations, we performed single cell cloning of the two populations targeted at either MYD88 and HBB by random colony picking. PCR analysis using primers annealing outside each homology arm determined that 17 out of 18 clones (94%) for HBB and 13 out of 21 clones (62%) for MYD88 possessed at least one integration (Figure 2b and 2c). Editing occurred with such great frequency that we were even able to obtain a high percentage of bi-allelic integration events for HBB (74% of the screened clones). For MYD88, we obtained mostly mono-allelic clones (52%) and 10% bi-allelic clones (Figure 2c-d) . We also performed off-target analysis at the two most probable off-target sites for both HBB and MYD88 sgRNAs identified by the COSMID target prediction tool 7, [10] [11] [12] [13] . This analysis showed off-target activity for both sgRNAs with 16 out of 18 clones for HBB and 19 out of 21 clones for MYD88 harboring off-target NHEJ events at one or both off-target sites (Supplemental figure 1a-d) . Thus, high frequencies of on-target editing can be accompanied by high frequencies of INDELs, though the INDELs are occurring at sites of no known biologic significance.
We next tested our system in a disease-relevant iPSC line homozygous for the Glu6Val sickle cell disease (SCD)-causing mutation 14 . Toward this end, we used a previously used AAV6 donor vector (Supplemental figure 2 that corrects the disease SNP (T→A) and introduces five silent mutations with sgRNA target sequence to prevent Cas9 from re-cutting and disrupting the gene 7 ( Figure 3a ). Combining this SCD-correction donor and Cas9 RNP, we targeted the SCD iPSC line using the optimized protocol, and droplet digital PCR (ddPCR) analysis showed 63% allele correction ( Figure 3b ). As before, we confirmed these results using single cell cloning followed by sequencing, which confirmed the high correction frequency with 15 out of 22 corrected clones (68%; Figure 3c ). Off-target analysis identified one corrected clone that did not contain off-target edits at the previous two off-target sites for the HBB sgRNA (clone #8; Figure 3d ).
In summary, our data confirms that Cas9 RNP and AAV6 is able to mediate targeted integration of large genes in ESCs and iPSCs at two different loci as well as precisely correct a diseasecausing mutation in a patient-derived iPSC line, all at high frequencies. Importantly, these high editing frequencies enable population-based studies without the requirement for selection markers or large scale single cell cloning. Although clones were found to contain mutations at predicted off-target sites, none of these sites for either guide lie within or near genes are thus unlikely to elicit a significant cellular effect. However, this finding highlights the importance of careful sgRNAs selection. Specificity may be enhanced using engineered Cas9 variants with higher specificity 15 , truncated or chemically modified sgRNAs with lower affinity for offtargets 10 or by careful titration of Cas9 RNP amounts. In fact, we did observe higher specificity when using the CB-150 electroporation program and with lower amounts of Cas9 (Supplemental
In addition to the highly improved editing frequencies in hPSCs using the Cas9/AAV6 system, we also demonstrated efficient integration of a large 2.2kb construct. This approach, using AAV6 to deliver donors up to 4.5kb, makes it possible to perform editing by cDNA knock-in in hPSCs as well, a strategy that would be critical for diseases with loss-offunction mutations scattered throughout a particular gene and would also be easily applied as a tool to generate genetically engineered human pluripotent cells for a variety of research purposes, such as to create stable transgenic lines or reporter lines.
In conclusion, we present a selection-free, one-step editing protocol that addresses insert size limitations and low editing efficiencies that have hindered the development of pluripotent stem cell technologies as disease models and gene correction therapies. 
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Materials & Methods:
Cell culture
Human ES H9 cells (WiCell) were used for MYD88 and HBB editing, and the iPSC lines described in figure1c were the following: line 1= 1759, line 2=iLC13-F1, line 3= iAM9-M2, line 4=TkDA3-4, line 5=iSB7-M3. TkDA3-4 iPSCs and iPSCs derived from SCD patient were established from human dermal fibroblasts (Cell Applications Inc) as described previously 16, 14 .
Cell lines 1759, iLC13-F1, iAM9-M2, and iSB7-M3 were established from human T cells as described previously 17 . Cells were maintained in mTeSR1 (STEMCELL technologies) on feeder free Matrigel (Corning)-coated plate. Subculture was performed every 5-6 days by EDTA method. For 1 day after plating, 10 µM Y-27632 (Tocris) was added to the medium. 
Electroporation and transduction
ESCs
Flow cytometry
For measuring targeted editing frequency, cells were harvested. Then cells were washed with PBS containing 1% human albumin and 0.5 mM EDTA. Data was acquired using an Accuri C6 plus flow cytometer (BD biosciences).
AAV Production
GFP integration donor containing UbC promoter, turboGFP, and bGH polyA targeting the HBB and MYD88 loci as well as the SCD corrective donor, were cloned into pAAV-MCS plasmid (Agilent Technologies) containing AAV2 ITRs. The HBB donor creates an insertion of 2.2kb within exon 1 of HBB and contains left and right homology arms that are 540bp and 420bp, respectively, and flank the Cas9 cut site. The MYD88 donor creates an insertion of 2.3kb within exon 1 of MYD88 and contains left and right homology arms that are 480bp and 450bp, respectively, and flank the Cas9 cut site. The SCD corrective donor contains a total of 2.4 kb sequence homology surrounding the Glu6Val mutation 7 . AAV vectors were produced as described previously with slight modification 18 . Each 15cm 2 dish of 293FT cells (Life Technologies) was transfected using PEI along with 6µg ITR-containing plasmid and 22µg pDGM6 (gift from D. Russell), carrying AAV6 cap, AAV2 rep, and adenoviral helper genes.
72h post-transfection, cells were harvested, lysed by freeze-thaw cycles, incubated at 37°C for 45min with TurboNuclease at 250 U/mL (Abnova), and purified using an iodixanol density gradient by ultracentrifugation at 237K g for 2h at 18°C. AAV6 vectors were extracted from the 60-40% iodixanol interface and exchanged into PBS with 5% sorbitol using an Amicon centrifugal filter 100K MWCO (Millipore Sigma) following the manufacturer's instructions.
Pluronic acid was added to dialyzed vector solution to a final concentration of 0.001%, aliquoted, and stored at −80°C until use. Vectors were titered using qPCR to measure vector genome concentration as described previously 19 .
Genotyping and sequence analysis
HBB and MYD88 ESC clones were amplified with the following primers to check for integration: 
MYD88-FW
Statistical analysis
All data are presented as means ± SD. Error bars are based on SEM. The statistical significance of the observed differences was determined with two-tailed Student's t tests for pairwise comparisons. b. Primer sequences used to amplify off-target regions. PCR for off-target analysis was done using Phusion Polymerase and gel extracted for sequencing.
c. Off-target analysis for both MYD88 and HBB clones for CA137 nucleofection protocol and CB150. Both were nucleofected using the optimized Cas9 RNP protocol (150µg). CA137 yields clones with a greater amount of off-target activity. Off-target is considered having indels at one or both of the regions analyzed. WT sequences have no indels at either region. 
